Abstracts

Gender Affirmation and Incentives for Long-Acting PrEP: Stated Preferences of Transgender Adults

Background: Transgender and nonbinary (trans) people face a disproportionately high HIV risk, yet adherence to pre-exposure prophylaxis (PrEP) remains low. Conventional approaches to PrEP programming have not sufficiently engaged trans populations. Gender affirmation and conditional economic incentives could help improve the uptake of PrEP, but user-centered approaches are needed to inform the optimal design of…

Uptake of Long-Acting Injectable Antiretroviral Therapy in Florida: An Assessment of EHR Data

Background: In January 2021, the US Food and Drug Administration approved the first long-acting injectable antiretroviral therapy (LAI ART) regimen, cabotegravir/rilpivirine, providing an alternative to daily oral regimens. However, scarce literature exists on the uptake of LAI ART using real-world data. Leveraging electronic health records from a large clinical research network in the Southern US…

Implementing Long-Acting ART in a Community Health Center: Insights and Early Outcomes

Background: Long-acting injectable Cabotegravir-Rilpivirine (CAB-RPV LAI) offers people living with HIV (PLWH) a safe and effective alternative to daily oral ART. In 2021, Whitman-Walker Health, a Federal Qualified Health Center (FQHC), began scaling up implementation of CAB-RPV LAI in appropriate patients. Methods: A multidisciplinary working group developed a protocol for providers and a workflow to…

Stigma in Young Kenyan Women Offered PrEP in a Peer-Supported, Community-Based PrEP Delivery System

Background: PrEP and HIV stigma are common and potential barriers for PrEP use. We used multiple approaches to measure stigma among young women accessing PrEP in a trial of a novel, peer-supported, community-based delivery system. Methods: In Kisumu, Kenya, 18-24-year-old women were recruited at PrEP initiation (July 2021-March 2022) and followed for 6 months. Participants…